The Week in Review: April 6 – April 13, 2018

Friday, April 13, 2018 News Recap: Canada: Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...

8 reports on liver cancer outcomes with HCV, DAA therapy

Patients with hepatitis C have an increased risk for disease progression to cirrhosis and potentially hepatocellular carcinoma. Recent studies have focused on defining liver cancer risks related to HCV progression and the rates of liver cancer after HCV clearance with new direct-acting antivirals. Several recent studies refute previous data suggesting that DAA therapy may increase the risk for liver cancer. Rather, researchers have found it more likely th

The Week in Review: March 2 – March 9, 2018

Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...

Newer drugs make hepatitis C-positive kidneys safe for transplant

People who received kidneys from donors infected with hepatitis C did not become ill with the virus, thanks to treatment with newer drugs that can cure the disease, a small study reports. Ten patients not previously infected with hepatitis C took doses of powerful antiviral medications before and after receiving the transplants. None of the patients developed chronic infections, researchers report online March 6 in the Annals of Internal Medicine. The fin

The Week in Review: January 26 – February 2, 2018

Friday, February 2, 2018 News Recap: From the Uh-Oh Department: HCV Can Reactivate with Treatment of Non-hepatic Cancer. Hepatitis C virus (HCV) reactivation occurred in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment. Compensation Update: Compensation – New Update for 86-90 Late Claims. If you or a family member received a blood transfusion o...

SVR for HCV with no advanced liver disease greatly reduces mortality risk

Patients with hepatitis C without advanced liver disease who achieved sustained virologic response with direct-acting antiviral therapy had significantly reduced all-cause mortality rates compared with both treated patients who did not achieve SVR and untreated patients, according to a recently published data. “These data strongly support a clinically significant benefit of DAA treatment in patients without clinically apparent advanced liver disease and e

The Week in Review: September 1 – September 8, 2017

Friday, September 8, 2017 News Recap: She thought her mystery ailment was cancer, but bloodwork revealed a surprise This is an amazing story ...but it could happen to anyone, and we know this because we hear these kinds of stories often. This is why it is so important that Boomers be tested for hepatitis C. Gail Wells got really sick and nobody could figure out why. They looked for cancer, for multiple sclerosis, for vitamin deficiencies, and then s...

HCV treatment found safe and effective in individuals with kidney disease

A new study indicates that direct-acting antiviral therapy is safe and effective in patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection. The study, which appears in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN), also found that treatment may help improve some patients' kidney function. HCV infection—which often causes liver disease—is common in patients with CKD, and it increases their

No valid evidence $40,000 miracle drug cures hepatitis C – study

Note from CD:  Woke up to this new report this morning and almost got hysterical.  Whatever the financial/political motivation behind this report, I know I speak for many others in the HCV community (patients and physicians) who KNOW that this is NOT TRUE. While, unfortunately, some with late-stage disease although they have cleared the virus have not improved (because they were treated too late and too much damage was done), we know that the DAAs work, re

The Week in Review: March 17, 2017 – March 24, 2017

Friday, March 24, 2017 News Recap Well, if you've been up to our site and seen the daily news posts you will have seen that new drug access policies have now come into effect in BC and Quebec, as well as Ontario. It looks like the slate is the same for these 3 provinces, and we are listing what's available in BC so you can make sense of it.  For more information on the expanded access criteria in Quebec see here, and in particular the note from CD. ...